Galderma Global Study Reveals True Burden of Rosacea and Encourages Healthcare Professionals to Look 'Beyond the visible'

PR73816

LAUSANNE, Switzerland, June 1, 2018 /PRNewswire=KYODO JBN/ --

Galderma today released the findings of a global survey highlighting the need

for dermatologists and doctors to proactively open a dialogue with patients

about the true burden of rosacea and ways in which they can work together to

achieve 'clear' (IGA 0) skin*. In the form of an expert-authored report

entitled Rosacea: Beyond the visible, available on the British Medical Journal

(BMJ) website, the data reveals the true extent of the psychosocial burden of

the disease. Every second patient reported that they would potentially be

willing to trade six months or more of their life to cure rosacea.[1]

Additionally, over half of those who have worked at least one hour in the past

seven days (55%) admitted that their health problems have impacted on their

work productivity.[1]

To view the Multimedia News Release, please click:

https://www.multivu.com/players/uk/8341651-galderma-global-study-rosacea/  

People who are 'clear' also tend to have fewer doctors visits and say that

their health problems had no effect (rated 0 - 2 out of 10) on their work

productivity vs. those who were 'almost clear'.[1] Despite the availability of

treatments and multiple healthcare professional (HCP) visits, only 14% of

patients surveyed rated themselves as 'clear' of symptoms at the time of

reporting, highlighting the extent of the unmet need.[1] People who were

'clear' were significantly less likely to be forced into modifying their daily

behavior even in comparison to those who were 'almost clear' (21% vs 16%

p less than or equal to 0.05).[1]

Rosacea affects more than 40 million people worldwide and is most common in

people aged between 30 and 50.[2] It is a visible and relapsing condition,

meaning that patients experience periods of flare-ups, and every individual's

experience is different, making it a complex disease to treat. Rosacea: Beyond

the visible offers useful insights into the emotional, psychological and

societal impact of the condition. According to the findings, there is a

disease-related impact on patients' quality of life. Rosacea can have a high

impact at any severity, with 82% of people surveyed feeling that their rosacea

is not totally controlled and 86% substantially modifying their behavior and

daily lives to avoid triggering flare-ups.[1]

"This research alerts us to the reality that people with rosacea can feel like

they are stuck in an unwinnable situation - judged on their appearance, but

also worried they will be blamed or viewed as superficial if they seek help. We

need to open the discussion surrounding the burden of rosacea and ensure people

are comfortable talking about the impacts this illness can have on their

lives.  

"We can help make a difference by opening the conversation with patients on the

impact of rosacea to identify the more vulnerable 'high burden' individuals and

implement a tailor-made treatment approach," comments Dr Jerry Tan, Adjunct

Professor, Western University, Windsor, Ontario, Canada and one of the study

authors.

The survey asked 710 patients diagnosed with rosacea and 554 dermatologists and

general practitioners (GPs) in six different countries (France, Germany, Italy,

UK, Canada and the US) questions about their experience of living with, or

treating patients that are living with, rosacea.

Key findings include:

Addressing the impact of rosacea remains an unmet need

The burden of rosacea goes beyond what patients feel physically and

emotionally, the knock-on effect also impacts wider society and medical

systems[1]

86% of patients modify their behavior to manage their symptoms, with one in

five making substantial changes to their daily life (such as avoiding social

interaction, activities with friends etc)[1]

People who report that rosacea has a very large impact on their life visit

their doctor more than twice as often as those whose quality of life is less

severely impacted (9.9 ±10.6 vs 4.4 ±3.2 visits per year)[1]

The number of patients visiting an emergency room (ER) in the past 12 months as

a result of their rosacea varied from 13-26% across different countries[1]

More than half of rosacea patients who worked in the past seven days for at

least one hour (55%) report that their health problems affect their work

productivity[1]

There is a need to open the dialogue between dermatologists/GPs and patients on

the burden of rosacea

People with rosacea may feel embarrassed or ashamed to talk about their disease

burden with over a third (37%) saying friends and family did not understand

their condition[1]

As people can be reluctant to discuss the true burden of their disease,

physicians can overestimate the impact of symptoms typically associated with

rosacea, but underestimate less-visible or well-known symptoms (such as

stinging, burning, itching and pain)[1]

82% of patients feel that their rosacea is not totally controlled[1]

Aiming for 'clear' can help relieve the burden of rosacea

Only 14% of people with rosacea rated themselves as 'clear' of symptoms at the

time of the global survey. This decreased to only 1% rating themselves 'clear'

when asked to consider the last year[1]

The extra step of reaching 'clear' can make a difference for the people who are

able to achieve it. 'Almost clear' isn't always good enough. It might only take

one pimple or pustule appearing on their face to upset a rosacea patient's

day[1]

Less than half of 'clear' patients reported rosacea had no impact on their

quality of life, significantly more than even 'almost clear' patients (49% vs

30% p less than or equal to 0.05)[1]

'Clear' may also mean rosacea controls each person's life less. People who were

'clear' were significantly less likely to be forced into modifying their daily

behavior even in comparison to those who were 'almost clear' (21% vs 16%

p less than or equal to 0.05)[1]

People who were 'clear' also tend to have a lower number of doctor visits even

compared to those who were 'almost clear' (4.8 ±5.3 vs 5.7 ±7.5 per year

p=NS)[1]

Healthcare professionals should aim to identify more vulnerable 'high burden'

patients, to implement a more individualized patient approach

Patients who report that rosacea has a severe impact on their quality of life

(DLQI>10) are typically younger and are significantly more likely to be

working, male and have stinging and burning skin sensations vs DLQI less than or equal to 10

patients[1]

Future investigation identifying contributing risk factors may reveal useful

markers or insights on high burden patients that can be used in clinical

practice

For related multimedia resources, please visit

http://www.epresspack.net/galderma-rosacea

* The success of rosacea treatment is usually defined as a score of 1 ('almost

clear') or 0 ('clear') on the 5-point Investigator Global Assessment (IGA)

scale. Several studies have shown that patients who achieve 'clear' (IGA 0), a

complete reduction in symptoms, experience an extended time to relapse and an

improved quality of life compared with patients who are 'almost clear' (IGA

1).[3]

About the BURDEN survey and the Rosacea: Beyond the visible online report   

The BURDEN survey was developed by Kantar Health as a self-administered online

survey and supported by Galderma. Participants were recruited using the Kantar

online panel. To maximize the sample size no quota was set up. Therefore, the

sample is not representative of the rosacea population of each country;

consequently, the results of this study could be affected by selection bias and

cannot be inferred to the whole rosacea population. Rosacea: Beyond the visible

was developed under the direction and sponsorship of Galderma International,

survey was conducted by Kantar Health with writing support provided by Emma

Waring, Havas Life Medicom.

About Rosacea   

Rosacea is a common inflammatory skin disease that presents variable clinical

characteristics, of which the most common are flushing, permanent erythema, and

inflammatory lesions. It mainly affects the central areas of the face, such as

the cheeks and nose. The disease can affect both adult men and women, usually

after the age of 30. Additionally, symptoms such as stinging, burning and

increased sensitivity of the skin are common. The eyes are often affected, and

might present as red, dry or itchy.

Although the cause of the disease is still under debate, various trigger

factors are known, including spicy foods, alcohol, emotional stress,

sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites,

can also be found in the skin in an elevated quantity in people with rosacea.

Rosacea may worsen over time if left untreated. People that suspect they suffer

from rosacea should visit their dermatologist or healthcare provider for

diagnosis and discuss what treatment is right for them. Because rosacea is a

highly visible disease, it is known to cause embarrassment and anxiety in some

patients, which in turn may cause frustration and have a negative impact on

their social life.

About Galderma

Galderma, Nestlé Skin Health's medical solutions business, was created in 1981

and is now present in over 100 countries with an extensive product portfolio to

treat a range of dermatological conditions. The company partners with health

care practitioners around the world to meet the skin health needs of people

throughout their lifetime. Galderma is a leader in research and development of

scientifically-defined and medically-proven solutions for the skin. For more

information, please visit http://www.galderma.com

References:  

Rosacea: Beyond the visible online report, BMJ Hosted Website

(http://hosted.bmj.com/rosaceabeyondthevisible). Last accessed: June 2018

Shanler S, Ondo A. Successful treatment of the erythema and flushing of rosacea

using a topically applied selective a1 adrenergic receptor agonist,

oxymetazoline [abstract taken from J Am Acad Dermatol. 2008;58(2): AB9].

Presented at: American Academy of Dermatology 66th Annual Meeting; February

1-5, 2008; San Antonio, TX

Webster G et al. J Dermatolog Treat. 2017;28(5):469-474

     (Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg )

     https://www.multivu.com/players/uk/8341651-galderma-global-study-rosacea/

Source: Galderma